0000950170-24-064820.txt : 20240524
0000950170-24-064820.hdr.sgml : 20240524
20240524193356
ACCESSION NUMBER: 0000950170-24-064820
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240523
FILED AS OF DATE: 20240524
DATE AS OF CHANGE: 20240524
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KARBE FRANK
CENTRAL INDEX KEY: 0001276700
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39094
FILM NUMBER: 24985977
MAIL ADDRESS:
STREET 1: C/O MYOVANT SCIENCES INC.
STREET 2: 2000 SIERRA POINT PARKWAY, 9TH FLOOR
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001783183
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 824151574
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (877) 742-8466
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
4
1
ownership.xml
4
X0508
4
2024-05-23
0001783183
Phathom Pharmaceuticals, Inc.
PHAT
0001276700
KARBE FRANK
C/O PHATHOM PHARMACEUTICALS, INC.
100 CAMPUS DRIVE, SUITE 102
FLORHAM PARK
NJ
07932
true
false
false
false
false
Common Stock
2024-05-23
4
A
false
10500
0
A
19500
D
Stock Option (Right to Buy)
10.30
2024-05-23
4
A
false
17500
0
D
2034-05-22
Common Stock
17500
17500
D
The Restricted Stock Units ("RSUs") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.
/s/ Molly Henderson, Attorney-in-Fact for Frank Karbe
2024-05-24